A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

This study has been withdrawn prior to recruitment.

( Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data. )

Study NCT00060554 Information provided by Schering-Plough

First Received: May 7, 2003 Last Updated: November 2, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been withdrawn prior to recruitment.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given